NCT07218380 2026-04-17
FORAGER-2
Eli Lilly and Company
Phase 3 Recruiting
Clinical Trials
58 trialsNCT03661320 2026-04-15
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04960709 2026-04-14
VOLGA
AstraZeneca
Phase 3 Active not recruiting
NCT04658862 2026-04-13
SunRISe-2
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05714202 2026-04-13
SunRISe-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT07419295 2026-04-13
TroFuse-031
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT05911295 2026-04-07
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Seagen Inc.
Phase 3 Active not recruiting
NCT06960577 2026-03-30
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca
Phase 3 Recruiting
NCT05037279 2026-03-20
EVER
Verity Pharmaceuticals Inc.
Phase 3 Recruiting
NCT07480356 2026-03-18
ADVANCED-3
Protara Therapeutics
Phase 3 Not yet recruiting
NCT07313891 2026-03-17
BOOST
Relmada Therapeutics, Inc.
Phase 3 Withdrawn
NCT03732677 2026-03-13
NIAGARA
AstraZeneca
Phase 3 Active not recruiting
NCT07464145 2026-03-11
RESCUE
Relmada Therapeutics, Inc.
Phase 3 Not yet recruiting
NCT04700124 2026-02-05
KEYNOTE-B15
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03682068 2026-02-03
NILE
AstraZeneca
Phase 3 Active not recruiting
NCT04165317 2026-01-22
CREST
Pfizer
Phase 3 Active not recruiting
NCT06331299 2026-01-15
UTOPIA
UroGen Pharma Ltd.
Phase 3 Active not recruiting
NCT06111235 2026-01-12
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
CG Oncology, Inc.
Phase 3 Active not recruiting
NCT03474107 2026-01-09
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Astellas Pharma Inc
Phase 3 Completed
NCT06747455 2025-12-23
BCG for Therapeutic Use Phase â…¢ Clinical Trial
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Phase 3 Recruiting
NCT04149574 2025-09-16
CheckMate 7G8
Bristol-Myers Squibb
Phase 3 Terminated
NCT03924856 2025-08-28
KEYNOTE-866
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03924895 2025-08-28
KEYNOTE-905
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05704244 2025-08-28
Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)
Ferring Pharmaceuticals
Phase 3 Active not recruiting
NCT02807636 2025-02-24
IMvigor130
Hoffmann-La Roche
Phase 3 Completed
NCT04241185 2024-11-25
MK-3475-992
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05243550 2024-11-04
ENVISION
UroGen Pharma Ltd.
Phase 3 Active not recruiting
NCT05600322 2024-10-03
Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer
Photocure
Phase 3 Completed
NCT05136898 2024-09-19
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
Phase 3 Completed
NCT04209114 2024-06-27
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT04688931 2024-06-06
ATLAS
UroGen Pharma Ltd.
Phase 3 Terminated
NCT02603432 2024-03-27
JAVELIN Bladder 100
Pfizer
Phase 3 Completed
NCT06241755 2024-02-05
Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Chengdu CoenBiotech Co., Ltd
Phase 3 Recruiting
NCT02426125 2023-08-21
RANGE
Eli Lilly and Company
Phase 3 Completed
NCT02449239 2023-07-24
VISTA
Sesen Bio, Inc.
Phase 3 Completed
NCT02563561 2021-10-27
A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT03224182 2021-09-28
A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT02256436 2021-09-20
MK-3475-045
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00461591 2021-03-30
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT03335059 2020-04-15
RITE-USA
Medical Enterprises Ltd.
Phase 3 Terminated
NCT02302807 2019-08-01
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
Hoffmann-La Roche
Phase 3 Completed
NCT02560584 2018-07-02
A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting
Photocure
Phase 3 Completed
NCT02471495 2018-05-07
RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)
Medical Enterprises Europe B.V.
Phase 3 Withdrawn
NCT01469221 2017-12-15
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT00598806 2017-11-13
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT01310803 2017-10-05
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Endo Pharmaceuticals
Phase 3 Terminated
NCT01200992 2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3 Terminated
NCT01410565 2016-12-13
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT00625664 2016-05-05
CILAB
Sanofi
Phase 3 Completed
NCT02254915 2015-04-01
SHTC-EUROPE-1
Medical Enterprises Europe B.V.
Phase 3 Withdrawn